Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Relat
Go back to Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Relat| (NASDAQ: OCGN) | Delayed: 1.23 -0.03 (2.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.26 | 52 Week High | $ | |||
| Open | $1.29 | 52 Week Low | $ | |||
| Day High | $1.30 | P/E | N/A | |||
| Day Low | $1.23 | EPS | $ | |||
| Volume | 4,144,940 | |||||
